HLA and drug-induced toxicity.

Area of Science:

• Pharmacogenomics
• Immunogenetics
• Drug Safety

Background:

• Advances in DNA-based molecular techniques and high-resolution HLA typing have superseded serological methods in identifying drug toxicity associations.
• Established links exist between specific Human Leukocyte Antigen (HLA) alleles and immunologically mediated drug reactions, including hypersensitivity and severe cutaneous adverse drug reactions.

Purpose of the Study:

• To highlight the role of HLA allele associations in understanding drug toxicities.
• To present HLA-B*5701 screening for abacavir hypersensitivity syndrome (ABC HSR) as a successful model for pharmacogenetic implementation.

Main Methods:

• Review of DNA-based molecular techniques and high-resolution HLA typing for identifying drug toxicity associations.
• Examination of documented HLA-drug toxicity associations, focusing on abacavir, carbamazepine, and allopurinol.
• Analysis of the implementation and impact of HLA-B*5701 screening for ABC HSR.

Main Results:

• Higher-resolution HLA typing has improved the discovery of drug toxicity associations, particularly for immunologically mediated reactions.
• HLA-B*5701 screening effectively prevents abacavir hypersensitivity syndrome (ABC HSR), supported by robust clinical and experimental evidence.
• The development of accessible laboratory tests and quality assurance programs facilitates the clinical integration of HLA-B*5701 screening.

Conclusions:

• HLA-B*5701 screening for ABC HSR serves as a successful paradigm for pharmacogenetic screening in clinical settings.
• The integration of pharmacogenetic principles, guided by HLA associations, enhances drug safety and personalized medicine.